1562 related articles for article (PubMed ID: 28624577)
21. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.
Nault JC; Couchy G; Balabaud C; Morcrette G; Caruso S; Blanc JF; Bacq Y; Calderaro J; Paradis V; Ramos J; Scoazec JY; Gnemmi V; Sturm N; Guettier C; Fabre M; Savier E; Chiche L; Labrune P; Selves J; Wendum D; Pilati C; Laurent A; De Muret A; Le Bail B; Rebouissou S; Imbeaud S; ; Bioulac-Sage P; Letouzé E; Zucman-Rossi J
Gastroenterology; 2017 Mar; 152(4):880-894.e6. PubMed ID: 27939373
[TBL] [Abstract][Full Text] [Related]
22. Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway.
Chen J; Zaidi S; Rao S; Chen JS; Phan L; Farci P; Su X; Shetty K; White J; Zamboni F; Wu X; Rashid A; Pattabiraman N; Mazumder R; Horvath A; Wu RC; Li S; Xiao C; Deng CX; Wheeler DA; Mishra B; Akbani R; Mishra L
Gastroenterology; 2018 Jan; 154(1):195-210. PubMed ID: 28918914
[TBL] [Abstract][Full Text] [Related]
23. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
Liu H; Shen J; Lu K
Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
[TBL] [Abstract][Full Text] [Related]
24. Contradictory intrahepatic immune responses activated in high-load hepatitis C virus livers compared with low-load livers.
Ishibashi M; Yamaguchi H; Hirotani Y; Sakurada A; Endo T; Sugitani M; Takayama T; Makishima M; Esumi M
Arch Virol; 2018 Apr; 163(4):855-865. PubMed ID: 29248968
[TBL] [Abstract][Full Text] [Related]
25. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.
Zhang M; Pang HJ; Zhao W; Li YF; Yan LX; Dong ZY; He XF
BMC Cancer; 2018 May; 18(1):511. PubMed ID: 29720116
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients.
Zhao Q; Xiao X; Wu Y; Wei Y; Zhu LY; Zhou J; Kuang DM
Eur J Immunol; 2011 Aug; 41(8):2314-22. PubMed ID: 21674477
[TBL] [Abstract][Full Text] [Related]
27. Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma.
Rohr-Udilova N; Klinglmüller F; Schulte-Hermann R; Stift J; Herac M; Salzmann M; Finotello F; Timelthaler G; Oberhuber G; Pinter M; Reiberger T; Jensen-Jarolim E; Eferl R; Trauner M
Sci Rep; 2018 Apr; 8(1):6220. PubMed ID: 29670256
[TBL] [Abstract][Full Text] [Related]
28. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.
Yarchoan M; Xing D; Luan L; Xu H; Sharma RB; Popovic A; Pawlik TM; Kim AK; Zhu Q; Jaffee EM; Taube JM; Anders RA
Clin Cancer Res; 2017 Dec; 23(23):7333-7339. PubMed ID: 28928158
[No Abstract] [Full Text] [Related]
30. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection.
Désert R; Rohart F; Canal F; Sicard M; Desille M; Renaud S; Turlin B; Bellaud P; Perret C; Clément B; Lê Cao KA; Musso O
Hepatology; 2017 Nov; 66(5):1502-1518. PubMed ID: 28498607
[TBL] [Abstract][Full Text] [Related]
31. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
Li G; Liu D; Cooper TK; Kimchi ET; Qi X; Avella DM; Li N; Yang QX; Kester M; Rountree CB; Kaifi JT; Cole DJ; Rockey DC; Schell TD; Staveley-O'Carroll KF
J Hepatol; 2017 Jan; 66(1):75-85. PubMed ID: 27520877
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.
Umemoto Y; Okano S; Matsumoto Y; Nakagawara H; Matono R; Yoshiya S; Yamashita Y; Yoshizumi T; Ikegami T; Soejima Y; Harada M; Aishima S; Oda Y; Shirabe K; Maehara Y
J Gastroenterol; 2015 Jan; 50(1):65-75. PubMed ID: 24509608
[TBL] [Abstract][Full Text] [Related]
33. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.
Chew V; Lai L; Pan L; Lim CJ; Li J; Ong R; Chua C; Leong JY; Lim KH; Toh HC; Lee SY; Chan CY; Goh BKP; Chung A; Chow PKH; Albani S
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5900-E5909. PubMed ID: 28674001
[TBL] [Abstract][Full Text] [Related]
34. Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas.
Castven D; Fischer M; Becker D; Heinrich S; Andersen JB; Strand D; Sprinzl MF; Strand S; Czauderna C; Heilmann-Heimbach S; Roessler S; Weinmann A; Wörns MA; Thorgeirsson SS; Galle PR; Matter MS; Lang H; Marquardt JU
Oncotarget; 2017 Jul; 8(30):48688-48700. PubMed ID: 28415775
[TBL] [Abstract][Full Text] [Related]
35. Intratumoral regulatory T cells with higher prevalence and more suppressive activity in hepatocellular carcinoma patients.
Wu H; Chen P; Liao R; Li YW; Yi Y; Wang JX; Cai XY; He HW; Jin JJ; Cheng YF; Fan J; Sun J; Qiu SJ
J Gastroenterol Hepatol; 2013 Sep; 28(9):1555-64. PubMed ID: 23517245
[TBL] [Abstract][Full Text] [Related]
36. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
37. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
Ostroumov D; Duong S; Wingerath J; Woller N; Manns MP; Timrott K; Kleine M; Ramackers W; Roessler S; Nahnsen S; Czemmel S; Dittrich-Breiholz O; Eggert T; Kühnel F; Wirth TC
Hepatology; 2021 Apr; 73(4):1399-1418. PubMed ID: 32716559
[TBL] [Abstract][Full Text] [Related]
38. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
39. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.
Di Blasi D; Boldanova T; Mori L; Terracciano L; Heim MH; De Libero G
Cell Mol Gastroenterol Hepatol; 2020; 9(2):195-218. PubMed ID: 31445190
[TBL] [Abstract][Full Text] [Related]
40. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
Mukaida N; Nakamoto Y
World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
